Genscript Biotech
GenScript Biotech Corporation is a Chinese biotechnology enterprise that provides life sciences contract research reagents, biological development services, and cell therapy products worldwide. The company operates through four main business segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products through Bestzyme, and Cell Therapy through Legend Biotech. Its primary revenue drivers consist of gene synthesis and peptide manufacturing services, bioprocess development fees, milestone and royalty payments from CAR-T cell therapies, and commercial sales of industrial enzymes. GenScript Biotech holds a leading position in the global gene synthesis services market, catering to academic, pharmaceutical, and biotech research clients across North America, Europe, and the Asia-Pacific region. The enterprise focuses on expanding its clinical CAR-T cell therapy commercialization, scaling biological manufacturing facilities, advancing contract development capabilities, and innovating synthetic biology applications. GenScript Biotech Corporation is headquartered in Nanjing, China, and its common shares are publicly listed and traded on the Hong Kong Stock Exchange.
13 of the funds FundTelligence covers report a position in Genscript Biotech.
- Legal name
- Genscript Biotech Corp
- Sector
- Health Care
- Country
- China
- Funds holding it
- 13
Funds holding Genscript Biotech
- T. Rowe Price Asian ex Jp Equity — T. Rowe Price · 1.23 % (full portfolio disclosed, September 2026)
- SEB Asienfond ex Japan — SEB · 0.12 % (full portfolio disclosed, June 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.09 % (full portfolio disclosed, September 2026)
- Storebrand Emerging Markets Plus — Storebrand · 0.07 % (full portfolio disclosed, October 2026)
- DNB Emerging Markets Index — DNB · 0.06 % (full portfolio disclosed, September 2026)
- SEB Emerging Marketsfond — SEB · 0.05 % (full portfolio disclosed, June 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.05 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.04 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 13 funds holding it.